From August 24, 2023 to September 30, 2023, the company has repurchased 533,100 shares, representing 0.49% for CNY 34.05 million. With this, the company has completed the repurchase of 533,100 shares, representing 0.49% for CNY 34.05 million under the buyback announced on August 24, 2023.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
62.32 CNY | -1.81% | -1.83% | -4.27% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.27% | 931M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- 301096 Stock
- News Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
- Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.